Increased levels of CA-125 are seen in prostate cancer [71], lung carcinoma [72], colorectal carcinoma [73], ovarian epithelial cancers [74], endometrial carcinoma [75], cervical carcinoma [76], pancreatic carcinoma [77], and lymphoma [78]. This evidence concerns the gene MUC16 and colorectal carcinoma.